Pre-market trend | CONSUN PHARMA (1681.HK) 5/6 moderately increased with volume, is capital flowing back into the pharmaceutical sector?

CONSUN PHARMA has recently shown a steady upward trend, with an increase of approximately 12.27%. The MACD daily bullish signal is gradually being established, with the fast and slow lines crossing above the zero axis, which usually indicates that the medium-term trend is transitioning from a consolidation phase to an upward breakout. The trading volume is about HKD 72.39 million, which, although not a large absolute amount, has significantly increased compared to the stock's historical average daily volume, indicating a rise in capital participation. The stock price is steadily rising, and the short-term moving averages are beginning to turn upward, forming an initial bullish arrangement. On the news front, the overall recovery trend in the pharmaceutical sector is evident. The Hong Kong stock biopharmaceutical index has stabilized and rebounded, with AKESO rising over 4% on the day and BEONE MEDICINES increasing nearly 3%, showing clear signs of capital returning to the sector. As a leader in the traditional Chinese medicine nephrology field, CONSUN PHARMA has a stable product matrix and excellent cash flow performance, making it a defensive yet flexible choice in the rotation of the pharmaceutical sector. Additionally, the domestic medical insurance policy's supportive stance towards traditional Chinese medicine remains unchanged, and the impact of centralized procurement on exclusive varieties is limited. The company's fundamentals are relatively certain, attracting some funds seeking stable returns. From a technical perspective, the current stock price is operating above the 5-day and 10-day moving averages, with both moving averages trending upward and maintaining a moderate distance, forming a step-like support. If today's trading volume remains above HKD 70 million and holds above the 5-day moving average, the upward trend is expected to continue. Attention should be paid to the previous high-pressure zone above, as a breakthrough may open up new upward space. The correlation between the Hong Kong pharmaceutical sector and the A-share market is worth noting, as the A-share market has also been active in the innovative drug sector recently